CANCER IMMUNOLOGY

A dendritic cell target for immunotherapy

+ See all authors and affiliations

Science  31 Oct 2014:
Vol. 346, Issue 6209, pp. 597
DOI: 10.1126/science.346.6209.597-a

A dendritic cell (blue) engages a T cell (yellow)

CREDIT: C. BICKEL/SCIENCE

Cancer immunotherapies work by activating T cells to kill tumors. Antigen-presenting cells (APCs), such as dendritic cells and macrophages, activate T cells by engaging protein receptors on the T cell surface. This then tells the T cells to attack the tumors. But T cells typically cannot attack tumors because the immunosuppressive microenvironment of tumors keeps APCs from turning these signals on. Broz et al. now report, however, that low numbers of dendritic cells capable of activating T cells exist in tumors in mice. T cell–mediated clearance of tumors depended on these cells. In humans, an increased genetic signature of these cells correlated with better outcomes in a variety of tumor types.

Can. Cell 10.1016/j.ccell.2014.09.007 (2014).

Navigate This Article